Details for Patent: 10,011,637

Which drugs does patent 10,011,637 protect, and when does it expire?

Patent 10,011,637 protects TRULANCE and is included in one NDA.

This patent has twenty-three patent family members in seventeen countries.

Summary for Patent: 10,011,637

Title:	Ultra-pure agonists of guanylate cyclase C, method of making and using same
Abstract:	The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Inventor(s):	Shailubhai; Kunwar (Audubon, PA), Comiskey; Stephen (Doylestown, PA), Feng; Rong (Langhorne, PA), Bai; Juncai (North Augusta, SC), Zhang; Ruoping (North Augusta, PA), Jia; Jun (Shanghai, CN), Zhou; Junfeng (Shanghai, CN), Zhao; Qiao (Shanghai, CN), Zhang; Guoqing (Shanghai, CN)
Assignee:	SYNERGY PHARMACEUTICALS, INC. (New York, NY)
Application Number:	14/896,019
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,011,637
Patent Claim Types: see list of patent claims	Compound; Process;

Drugs Protected by US Patent 10,011,637

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes				Y

International Family Members for US Patent 10,011,637

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014274812
Australia	2018226473
Australia	2020205349
Brazil	112015030326
Canada	2913737